Keymed Biosciences Announces 2026 H1 Results and Business Updates

EarningsKangyuedaPositive

AI Analysis

Summary

Keymed Biosciences announced H1 2026 interim results with total revenue of RMB617 million, with core product Kangyueda achieving sales of RMB393 million, representing 132% year-over-year growth.

Financial Highlights

Revenue

RMB617 million

Importance:3/10

Sentiment:

0.60

earningsrevenue growthChinacommercial stageH1 2026 results

Related Companies

$CHHE

Read the original article

Published by PR Newswire Pharma on August 21, 2026 9:13 AM

Read Original